pozelimab-bbfg (Veopoz)

^[1]^[2]

Indications

treatment of adult & pediatric patients >=1 year of age with CD55-deficient protein-losing enteropathy (CHAPLE disease)

unresolved Neisseria meningitidis infection
- interrupt treatment with VEOPOZ in patients with serious encapsulated bacterial infection

initial dose 30 mg/kg IV followed by weekly 10 mg/kg SC doses
- may increase to 12 mg/kg SC
maximum daily dose: 800 mg

human monoclonal IgG4 directed against the terminal complement protein C5
- blocks cleavage of C5 to C5a (anaphylatoxin) & C5b, thus blocking formation of the membrane-attack complex (C5b-C9) thus inhibiting cell lysis

↑ U.S Food & Drug Administration, Aug 18, 2023 FDA approves first treatment for CD55-deficient protein-losing enteropathy (CHAPLE disease) https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-first-treatment-cd55-deficient-protein-losing-enteropathy-chaple-disease
↑ Highlights of Prescribing Information VEOPOZ (pozelimab-bbfg) injection, for intravenous or subcutaneous use https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761339s000lbl.pdf